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OVERCOMING LOGISTICAL CHALLENGES IN PERFORMING INTERVEN-
TIONAL CLINICAL TRIALS IN THE LONG-TERM FOLLOW-UP (LTFU)
SETTING AFTER HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Dahlgren, C.J., Nguyen, H.-L., Choe, P., Boeckh, M. Fred Hutchinson
Cancer Research Center, Seattle, WA.
Background: Conducting interventional clinical trials according
to Good Clinical Practice (GCP) standards presents a formidable
challenge in the LTFU period following HCT. Challenges include
receiving blood specimens promptly from patients living in remote
locations, gaining patient and provider commitment to regular lab
testing and clinical assessments, and maintaining timely commu-
nication between providers and patients for clinical interventions.
Methods: We evaluated logistical aspects of conducting an inter-
ventional clinical trial in the LTFU setting. Data from a multi-
center, randomized placebo-controlled trial for prevention of late
CMV complications were examined for: geographic distribution of
patient location, feasibility of overnight shipment of specimens,
and time to appropriate intervention following results. Clinical
interventions consisted of (a) start of preemptive antiviral treat-
ment for positive CMV quantitative PCR result (b) interruption of
study drug administration and start of GCSF for any neutropenic
episode deﬁned by ANC1.000/uL and (c) adjusting dose of study
medication based on renal function. The study included 8 partic-
ipating sites. All samples were analyzed at FHCRC, the central site.
Results: 140 study participants were distributed over 112 cities and
36 states including Alaska. We received 3661 blood specimens
(90% were collected at off-site locations). From the time each
specimen was sent by overnight carrier, 85% were received by the
central site in 24 hours, 9% were received between 24-48 hours,
and 6% were received	48 hours. Treatment for CMV began after
a median of 1 (range 0-7) day(s) after the PCR result was obtained.
Upon report of the CMV PCR result to the provider, 26% of
patients were treated on the same day, 37% within 1 day, 26%
within 2 days, and 11% within 3 days. The median time from
awareness of neutropenia to holding study drug was 0 (range 0-3)
days; 81% of the patients held study drug on the same day of the
result, 5% within 1 day, 11% within 2 days, and 3% within 3 days.
Dose adjustment for renal function was implemented a median of
1 (range 0-2) day(s) upon obtaining the result. Of these renal
adjustments, 2% occurred on the same day, 95% within 1 day, and
3% within 2 days. Conclusions: This study demonstrates that
complex interventional randomized studies in the LTFU setting
are feasible, even if most participants live in distant locations, and
that therapeutic decisions can be made on a real-time basis.
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QUALITY OF LIFE, SPIRITUAL WELL-BEING, AND SURVIVAL POST-
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Morris, M.E., Lynch, J.C., Bociek, G., Bierman, P.J., Vose, J.M.,
Armitage, J.O. University of Nebraska Medical Center, Omaha, NE.
Introduction: Quality of life (QOL) is an important outcome in
the treatment of malignancy, including hematopoietic stem cell
transplant (HSCT). QOL is conceptualized as multi-dimensional
including physical, psychosocial, emotional, and spiritual well-
being (SWB). Purpose: A longitudinal QOL study of post-HSCT
recipients is being conducted at the University of Nebraska Med-
ical Center (UNMC) to evaluate changes over time in QOL and to
examine the relationship between patient, disease, and transplant
characteristics and QOL. Methods: Participants complete the
Medical Outcomes Survey SF-36, Functional Assessment of Can-
cer Therapy-Bone Marrow Transplant (FACT-BMT), and City of
Hope (COH) Medical Center-BMT survivor questionnaires at
baseline (pre-HSCT), day 100, and yearly post-HSCT. For each
subscale, the sample was dichotomized as 80th percentile ver-
sus 	 80th percentile of the baseline score, and clinical outcomes
compared between the two groups. Results of the baseline COH
SWB subscale, which includes questions regarding uncertainty,
purpose, hope, and peace, are reported here. Results: Between
September 2001 and June 2004, 172 participants received autolo-
gous HSCT for hematologic malignancy. Most (97%) were white,
non-Hispanic, 55% were male, and the median age at transplant
was 52 years (range 20-75). Median follow-up of surviving patients
is 24 months (range 12-49) and 44 (25%) patients had progressed
prior to analysis. The 3 year overall survival (OAS) rate for patients
with high (	9.0) SWB was 93% compared to 79% for patients
with lower SWB (P  .05, log rank test). However, baseline SWB
was not a statistically signiﬁcant predictor for event-free survival or
relapse rate. No other COH subscale scores were signiﬁcantly
related to clinical outcome nor were any FACT subscale scores.
Discussion: In this initial analysis, SWB at baseline is a signiﬁcant
predictor of OAS. Multivariate analysis is needed to determine if
the impact of SWB can be explained by other patient characteris-
tics such as co-morbidities or disease status at HSCT. Implica-
tions: Additional studies focusing on longitudinal spiritual assess-
ment and intervention are needed to determine the long-term
impact of SWB on QOL and survival.
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DOES IT MATTER WHEN A PATIENT IS REFERRED FOR INITIAL CON-
SULT FOR BLOOD AND MARROW TRANSPLANT
Campbell, S.W., Dale, I.L., Lyons, P.A., Tate, D.F. University of
Alabama at Birmingham (UAB) BMT Program, Birmingham, AL.
As data manager and bone marrow transplant coordinators at the
University of Alabama at Birmingham (UAB) Bone marrow Trans-
plant (BMT) Program, we are constantly seeking ways to help
facilitate better patient outcomes. We, as a group, asked the ques-
tion “Does it really matter when a patient is referred for blood and
marrow transplant?” A retrospective analysis of 45 patients with
hematological malignancies was done evaluating the appropriate-
ness of the time frame from diagnosis of disease to the initial
consultation with the BMT team and the overall outcomes based
upon the recommendations from the National Comprehensive
Cancer Network (NCCN) Guidelines. Of these 45 patients, 14
were deemed appropriate or early referrals, and 31 were deﬁned as
late for initial consultation with the BMT team during the 2004
calendar year. Fifty percent of the early referrals and 35% of the
late referrals (18 patients total) went on to receive a HSCT. There
were numerous reasons why the 27 patients failed to receive a
HSCT, some of which include patient choice, disease relapse, and
co-morbid conditions. Of the 18 patients who did receive a trans-
plant, 11 of those patients are still alive and well today. Overall,
based upon guidelines from the NCCN, our data supports early
referral versus late referral.
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WASHINGTON UNIVERSITY NURSING EXPERIENCE COORDINATING
PATIENT CARE ON A PHASE III TRIAL EVALUATING AMD3100 (MOZO-
BILTM), A NOVEL DRUG FOR STEM CELL MOBILIZATION
Devine, H., Larson, S., Comer, H. Barnes-Jewish Hospital/Washington
University Medical Center in St. Louis, St. Louis, MO.
AMD3100 (MOZOBILTM) is a novel agent which induces a
rapid increase in the number of stem cells in peripheral blood. It
appears to be safe and when combined with G-CSF may increase
the yield of stem cells compared to G-CSF alone. The optimum
mobilization occurs when the drug is scheduled the evening prior
to apheresis, creating a number of potential logistical difﬁculties
managing trials evaluating this agent. As we commenced accrual to
a phase III placebo controlled study comparing G-CSF alone to its
combination with MOZOBIL, we worked diligently to ensure
there were no gaps in patient care. Patient teaching strategies
included verbal instruction contrasting historical methods of stem
cell mobilization with this novel procedure as well as printed BMT
literature. All patients and their caregivers were offered involve-
ment in a patient education class. The RN coordinator was instru-
mental in creating the patient’s mobilization schema and further
collaborating with the clinical research associate, apheresis depart-
ment, stem cell laboratory, and the inpatient and outpatient treat-
ment areas. Since our medical center does not have an after hours
outpatient clinic, our patients received MOZOBIL/placebo on a
designated inpatient unit. Challenges with this approach occurred
when the inpatient unit was understaffed or had high acuity pa-
tients. Additionally, the inpatient RNs expressed concern regard-
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ing their unfamiliarity with this new method of stem cell mobili-
zation. The patients appreciated the inpatient RN’s assistance in
this protocol but were initially dissatisﬁed with the lack of privacy
on a busy inpatient unit. A private area on the inpatient unit was
later secured for study patients to be assessed and monitored. The
administration schedule created some frustration on the part of the
patients due to the long delay between study drug injection and
apheresis. Nevertheless, accrual to this trial at our institution has
been relatively brisk. Patient education, nursing coordination, and
collaboration with members of the BMT team were paramount in
our successful implementation of this study. Designated nursing
staff committed to clinical trials, as well as detailed, mandatory
inservices need to occur in order to implement a complex BMT
trial such as this. Our experience with this trial leads us to conclude
that in order to determine whether patients may beneﬁt from novel
BMT strategies, effective nursing teamwork, education, and col-
laboration will be essential.
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REDUCING ADMISSION RATES POST-STEM CELL TRANSPLANT UTILIZ-
ING AN EDUCATIONAL QUESTIONNAIRE TO ASSESS RETENTION OF
CAREGIVER KNOWLEDGE
Chadakhtzian, A., Barnes, Y., Hayashi, R.J., Shenoy, S. 1. Saint Louis
Children’s Hospital, Saint Louis, MO; 2. Washington University School
of Medicine, Saint Louis, MO.
Background and Aim: Caregivers and recipients of stem cell
transplants (SCT) undergo an educational process to understand,
anticipate, prevent, and seek appropriate intervention for trans-
plant related medical and social issues. A quality assessment ques-
tionnaire was developed to assess retention of pediatric SCT dis-
charge education. The aim was to (1) determine the feasibility of
administering a quality assessment questionnaire following SCT
education to caregivers in pediatric SCTs and (2) correlate admin-
istration with re-admission rates in the ﬁrst 100 days post SCT.
Methods: The questionnaire was randomly introduced to a group
of 13 caregiver(s) prior to discharge. Twelve non-consecutive care-
givers served as the control group. The questionnaire consisted of
10 multiple-choice questions for autologous and 15 for allogeneic.
Questions were directed at recalling the education they received.
Upon completion, all answers were reviewed with the caregiver(s).
Any incorrect answers were reviewed and the correct answer and
rationale provided. Re-admission rates were monitored in both
groups for the ﬁrst 100 days. Results: Twenty-ﬁve patients (12
control; 13 test subjects) were analyzed during a 17 month period,
March 2004 to July 2005. Compliance was 100% in the test group.
Patient age ranged from 19 months to 17 years; there were 18
males and 7 females. The test group consisted of 2 autologous
PBSCT (peripheral blood), 2 MSD (matched sibling) BMT, 3
MSD PBSCT, and 6 URD (unrelated donor) BMT. The control
group consisted of 2 autologous PBSCT, 5 MSD PBSCT, and 5
URD BMT. The test group re-admission rate was 5/13 (38%).
The control group re-admission rate over the same period was
9/12 (75%). Staff variables between the 2 groups were similar.
Conclusions: Utilization of this tool decreased the incidence of
re-admission. This study suggests there is value in development of
a quality assessment tool assessing the impact of transplant related
education for patient caregiver(s) prior to discharge. There is a
trend toward decreased re-admissions in the early post-transplant
period and may translate into less cost, better care and comfort for
the patient. Continued assessment of this in a larger cohort is
planned over an extended period to determine the beneﬁts of this
tool.
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RECOGNIZING INDICATIONS FOR PHOTOPHERESIS IN ACUTE AND
CHRONIC GRAFT-VERSUS-HOST DISEASE PATIENTS
Graham, H.J., Wade, J.C., Rizzo, J.D., Hari, P., Miels, S.,
Gruling, R.J., Sorensen, S.H. 1. Medical College of Wisconsin, Milwau-
kee, WI; 2. M. D. Anderson, Houston, TX.
Introduction: Extra Corporal Photopheresis (ECP) is currently
being used as an effective treatment for patients with Acute and
Chronic Graft-versus-Host Disease (GVHD). Treatment has been
initiated as early as 24 hours after conﬁrming the Graft-versus-
Host Disease to be refractory to corticosteroids. Although there is
no standard treatment for Chronic Graft-versus-Host Disease,
ECP has been utilized as treatment with promising results. Meth-
ods: Cumulative treatment records for patients with Acute and
Chronic Graft-versus-Host Disease that received photopheresis
were retrospectively reviewed. Indications, frequency, and appro-
priateness of photopheresis treatment were analyzed. Although
there were indications of improvement in patients with Acute and
Chronic Graft-versus-Host Disease while receiving photopheresis
treatments, it was difﬁcult to quantify positive or negative changes
in the patients’ physical assessment. It is important to recognize
early indications of Graft-versus-Host Disease in the allogeneic
blood and marrow transplant (BMT) population. Presented is an
assessment tool to facilitate recognition and follow-up of physical
indicators in patients with Acute and Chronic Graft-versus-Host
Disease (GVHD). This assessment tool was developed following
discussions with physicians and nurses in an effort to prospectively
quantify the response to therapeutic modalities. Additionally, this
tool will assist in identifying time of response and beneﬁts of
treatments. This tool is being validated prospectively on patients
currently undergoing ECP. Once validated, the instrument will be
placed in routine use. The ultimate goal is to develop a tool to
assist the clinician in providing an initial and ongoing physical
assessment both before and during photopheresis treatment. This
tool can assist in identifying improvements or changes in the
patient’s Acute or Chronic Graft-versus-Host Disease status.
Results and conclusion will be presented.
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PERIPHERAL BLOOD CD34 ENUMERATION AS PREDICTOR FOR AU-
TOLOGOUS HEMATOPOIETIC PROGENITOR CELL (HPC) COLLECTION
IN CHILDREN
Daum, C.D., Klinger, E.F., Neudorf, S.M., Sloan, V., Nourani, A.,
Casacchia, C. Children’s Hospital of Orange County, Orange, CA.
Purpose: The ability to accurately predict the collection of
adequate numbers of CD34 cells in children can minimize the
unnecessary placement of apheresis catheters and stem cell collec-
tions. We hypothesize that the numbers of peripheral blood
CD34 cells will predict successful collection of HPCs in children
and are a more accurate predictor of successful collection than
white blood count. Methods: We studied 28 potential candidates
for autologous stem cell transplantation. Diseases included neuro-
blastoma (n  7), medulloblastoma (n  8), non-Hodgkin’s lym-
phoma (n  4), acute promyelocytic leukemia (n  1), other solid
tumors (n  8). The age range of the patients was 11 months–20
years. All received chemotherapy followed by 10 mcg/kg/day G-
CSF (24), or GM-CSF (1), or G-CSF  GM-CSF (2), or
G-CSF  IL-11 (1). Peripheral blood counts were monitored a
minimum of twice weekly. When the WBC 	 1000/ul, peripheral
blood CD34 cells were enumerated by ﬂow cytometry. Apheresis
was initiated when the peripheral blood CD34 count was 	10/
mm3. Apheresis was performed with the goal of collecting 5 
10e6 CD34 cells/kg. Results: Twenty-two of 28 patients had
	10 CD34 cells/ul prior to apheresis. Three patients had CD34
counts between 5-10/ul and 3 patients had CD34 counts 	5/ul.
The median CD34 count for all patients was 23.5/ul (range 2-400).
Twenty-one of 22 patients with 	10 CD34 cells/ul had had 5 
10e6 CD34 cells/kg collected and one patient reached 4.8 
10e6 CD34 cells/kg after 2 collections. Patients with 	10
CD34 cells/ul required a mean of 1.41 collections to reach the
goal of 5 10e6 CD34/kg. All patients whose CD34 count was
5-10 achieved their target goal of 5  10e6 CD34 cells/kg in a
mean of 3.33 collections. Only 1 of 3 patients with 5 CD34
cells/ul reached the goal of 5  10e6 CD34 cells/kg although in
all 3 cases, 	1  10e6 CD34 cells/kg were collected. Twenty-
eight of 28 patients had a WBC 	1000/ul prior to collection and
the WBC did not correlate with the numbers of circulating
CD34 cells. Conclusions: We found that starting apheresis
when the CD34/ul was 10 consistently resulted in meeting the
target goal of collecting 	 5  10e6 CD34 cells/kg and that
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